Tareg 40. 80. 160 Tablets 40mg. 80mg. 160 mg FC tablets
PDF Leaflet Revision Date: 03 December 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of hypertension, post-myocardial infarction, and heart failure.
Dosage (summary)
80 mg or 160 mg once daily for hypertension; titrate from 20 mg to 160 mg twice daily for post-MI; start at 40 mg twice daily for heart failure.
Onset of Action / Duration
Onset: 2 weeks, Duration: 24 hours
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy; not established in breastfeeding.
Key Drug Interactions
- Potassium-sparing diuretics
- NSAIDs
- Lithium
Contraindications
- Hypersensitivity
- Angioedema history
- Severe renal impairment
- Pregnancy
- Bilateral renal artery stenosis
Common side effects
- Dizziness
- Hypotension
- Cough
- Fatigue
Counselling Points
- Monitor blood pressure regularly
- Avoid potassium supplements
- Report any signs of angioedema
Serious warnings
- Symptomatic hypotension in volume-depleted patients
- Risk of renal impairment
- Angioedema
Important Disclaimer
The Tareg 40. 80. 160 Tablets 40mg. 80mg. 160 mg FC tablets professional information leaflet below is the property of Novartis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
